title: Anti-HBs cellular immune response in kidney recipients before and 4 months after transplantation.
abstract: Patients with renal failure represent a population at risk for hepatitis B, since only 50 to 60% of them develop protective humoral responses after vaccination. As this could be due to an altered regulation of cellular immune responses, the objectives of the present study were to evaluate the proliferative abilities of lymphocytes from patients with chronic renal failure after stimulation in vitro with a mitogen (pokeweed mitogen [PWM]) or HBsAg. In order to differentiate between the immunodeficiency associated with renal failure and that due to immunosuppression posttransplantation, the same subjects were tested before and 4 months after kidney transplantation. The lymphoproliferation assay used was performed by flow cytometry, which is based on sequential analysis of the cell cycle and which allows analysis of cytokine production. Serologically, the group of 36 patients tested comprised 22% nonresponders, 30% poor responders, and 48% responders. Lymphocyte growth was observed for all patients after stimulation with PWM, indicating that these cells had the capacity to proliferate in vitro. The level of lymphoproliferation in response to PWM was significantly reduced after transplantation, yet both before and after transplantation, all serologic nonresponders developed cellular responses to at least two vaccines. No correlation between humoral and cellular responses was shown. Proliferating cells were lymphocytes, which mostly secreted interleukin 4 (IL-4) and IL-10 for the three serologic groups. This study suggests that even when repeated vaccination fails to induce significant antibody levels in patients with renal failure, specific HBs cellular responses develop, and these may prove to be efficient in protecting these patients against hepatitis B.
authors: Laboratoire d'Immunologie du CHU, Faculté de Médecine, 54500 Vandoeuvre les Nancy, France.
authors: Patricia
authors: P
authors: Aguilar
authors: Edith
authors: E
authors: Renoult
authors: Loraine
authors: L
authors: Jarrosson
authors: Marie Nathalie
authors: MN
authors: Kolopp-Sarda
authors: Christine Prin
authors: CP
authors: Mathieu
authors: Gilbert C
authors: GC
authors: Faure
authors: Michele
authors: M
authors: Kessler
authors: Marie C
authors: MC
authors: Bene
authors: Chantal
authors: C
authors: Kohler
authors: Anne
authors: A
authors: Kennel De March
mesh_terms: D000328:Adult; D000917:Antibody Formation; D002478:Cells, Cultured; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D006511:Hepatitis B Antigens / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular; D007676:Kidney Failure, Chronic / Q000150:complications; D016030:Kidney Transplantation / Q000009:adverse effects*; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens